Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T89 for Prevention and Treatment of Acute Mountain Sickness
NCT03552263Phase 2Completed
- Sponsor
- Tasly Group
- Start
- Jun 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Compound Danshen in acute mountain sickness (AMS), sponsored by Tasly Group. Started Jun 2018; status: completed.
02
Drugs
Compound Danshen
03
Conditions
acute mountain sickness (AMS)
Beyond the preview
Go deeper on NCT03552263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03552263.